Olmesartan safety called into question

A CLOUD hangs over the safety of antihypertensive agent olmesartan (Olmetec) following a clinical trial linking it to an increased risk of fatal cardiovascular events in patients with diabetes.

ROADMAP was a randomised controlled trial in more than 4000 type 2 diabetes patients receiving 40 mg of olmesartan or placebo, designed to show whether the antihypertensive agent could delay or prevent microalbuminuria.

Microalbuminuria onset was delayed by 23% in the olmesartan group, but 15 patients in the olmesartan group had fatal cardiovascular events compared